Welcome to our dedicated page for ZimVie news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZimVie stock.
ZimVie Inc. (Nasdaq: ZIMV) is a leading global life sciences company specializing in the dental and spine markets. Formed in March 2022 as an independent spin-off from Zimmer Biomet, ZimVie focuses on developing, manufacturing, and delivering a diverse portfolio of innovative products designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures.
Company Segments:
- Spine Products Segment: ZimVie offers an array of spine solutions, including implants, surgical tools, and bone graft substitutes. Significant advancements include the launch of the 4.5mm Mobi-C Cervical Disc, which provides pain relief and motion preservation for cervical disc degeneration.
- Dental Products Segment: The company delivers comprehensive dental solutions, including implants and digital care management systems. ZimVie is committed to driving peri-implant health and immediacy through its innovative dental product lines.
Recent Achievements:
- In October 2023, ZimVie celebrated the first U.S. implantation of its 4.5mm Mobi-C implant.
- In December 2023, the company received FDA clearance for its Vital™ Spinal Fixation System, designed for use with Brainlab Spine & Trauma Navigation.
Current Projects:
- ZimVie is actively co-marketing Brainlab Spine & Trauma Navigation alongside its Vital and Virage product lines, with plans to expand further in 2024.
- The company is also focused on the strategic sale of its spine business to H.I.G. Capital, expected to close in the first half of 2024. This move aims to streamline operations and sharpen focus on the dental sector.
Financial Health:
ZimVie continues to navigate its financial landscape with strategic initiatives like debt reduction and reallocation of resources to higher-growth dental markets. The company has paid down significant debt while maintaining a robust portfolio of products supported by extensive clinical evidence.
Partnerships:
ZimVie collaborates with leading organizations like Brainlab to enhance its product offerings, ensuring cutting-edge solutions in spine and dental care. These partnerships enable ZimVie to remain at the forefront of technological advancements in the medical device industry.
Rhea-AI Summary
ZimVie Inc. announces that over 2,000 children worldwide have been treated with The Tether™ Vertebral Body Tethering System, a market-leading technology for scoliosis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
-
Rhea-AI Summary
ZimVie Inc. expands its dental solutions for lab customers with the launch of Azure Multi-Platform Product Solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
-
Rhea-AI Summary
ZimVie Inc. to report Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.22%
Tags
Rhea-AI Summary
ZimVie launches Biotivity A/C Plus Membrane in the US
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
-
Rhea-AI Summary
ZimVie Inc. receives FDA approval for its Mobi-C Cervical Disc Hybrid Investigational Device Exemption (IDE) application, allowing enrollment of U.S. patients in a clinical study of cervical arthroplasty adjacent to fusion. Surgeons have implanted over 200,000 Mobi-C implants for cervical disc replacement since 2004. The study may lead to broadening the approved indications for cervical disc replacement, potentially benefiting more patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
-
Rhea-AI Summary
ZimVie Inc. has expanded its cooperation agreement with Brainlab to achieve compatibility between ZimVie's Vital and Virage fixation systems and Brainlab spine and trauma navigation technologies. ZimVie will also co-market the Brainlab technologies alongside its existing spine implant solutions globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
Rhea-AI Summary
ZimVie Inc. has received FDA approval for a smaller height of the Mobi-C Cervical Disc in seven footprints, allowing surgeons to address the anatomical needs of the U.S. patient population. The 4.5mm height implants expand the indications for cervical disc arthroplasty and provide greater flexibility for surgeons. ZimVie will commercialize the product in the U.S. this fall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
-
Rhea-AI Summary
ZimVie Inc. reported financial results for the second quarter ended June 30, 2023. Third party net sales were $224.9 million. The company had a net loss of ($23.4) million, with a net loss margin of (10.4%). Adjusted net income was $4.3 million, and diluted EPS was ($0.89). Adjusted diluted EPS was $0.17. Adjusted EBITDA was $29.7 million, with an adjusted EBITDA margin of 13.2%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
FAQ
What is the current stock price of ZimVie (ZIMV)?
The current stock price of ZimVie (ZIMV) is $14.57 as of November 5, 2024.
What is the market cap of ZimVie (ZIMV)?
The market cap of ZimVie (ZIMV) is approximately 400.5M.
What does ZimVie Inc. specialize in?
ZimVie Inc. specializes in the dental and spine markets, offering products such as implants, bone graft substitutes, and digital care management solutions.
When was ZimVie founded?
ZimVie was founded in March 2022 as an independent spin-off from Zimmer Biomet.
What are the two main operating segments of ZimVie?
ZimVie's business is organized into two segments: the spine products segment and the dental products segment.
What is the Mobi-C Cervical Disc?
The Mobi-C Cervical Disc is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis used for cervical disc reconstruction, approved by the FDA for reconstruction at both one and two levels (C3-C7).
What recent FDA clearance did ZimVie receive?
In December 2023, ZimVie received FDA clearance for its Vital™ Spinal Fixation System, designed for use with Brainlab Spine & Trauma Navigation.
Who is ZimVie selling its spine business to?
ZimVie has entered into a definitive agreement to sell its spine business to H.I.G. Capital, a leading global alternative investment firm.
How does ZimVie plan to use the proceeds from the spine business sale?
ZimVie intends to use the after-tax proceeds to reduce debt and focus on growing its dental business.
What are some of ZimVie's partnerships?
ZimVie collaborates with organizations like Brainlab to enhance its product offerings, particularly in spine and dental care.
Where is ZimVie headquartered?
ZimVie is headquartered in Westminster, Colorado, with additional facilities worldwide.
What markets does ZimVie serve?
ZimVie serves customers in over 70 countries worldwide, providing a comprehensive portfolio of dental and spine solutions.
ZimVie Inc.
Nasdaq:ZIMV
ZIMV Rankings
ZIMV Stock Data
400.46M
27.60M
1.93%
93.05%
1.59%
Medical Devices
Dental Equipment & Supplies
United States of America
PALM BEACH GARDEN